The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!
Gå frakoblet med Player FM -appen!
Graft Polymer UK CEO discusses Eurofins partnership to assess potential of lead asset targeting PTSD
MP3•Episoder hjem
Manage episode 443558575 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's promising preclinical program targeting mental health conditions such as post-traumatic stress disorder (PTSD). Partnering with Eurofins Discovery, Graft Polymer is testing its co-lead aminoindane series, a class of compounds that interact with serotonin, dopamine, and norepinephrine receptors. These compounds aim to reduce the human response to trauma, addressing the significant unmet need in PTSD treatment. "Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone," Tennyson explained, adding that current treatments are limited, leaving a large addressable market. With Eurofins Discovery's expertise in research services, Graft Polymer is moving forward quickly and expects preclinical results by the end of November. Watch the full interview for insights into this groundbreaking PTSD research and stay updated on Graft Polymer’s progress. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates. #GraftPolymer #AnthonyTennyson #EurofinsDiscovery #PTSDTreatment #PharmacologyTesting #MentalHea#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
606 episoder
Graft Polymer UK CEO discusses Eurofins partnership to assess potential of lead asset targeting PTSD
MP3•Episoder hjem
Manage episode 443558575 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's promising preclinical program targeting mental health conditions such as post-traumatic stress disorder (PTSD). Partnering with Eurofins Discovery, Graft Polymer is testing its co-lead aminoindane series, a class of compounds that interact with serotonin, dopamine, and norepinephrine receptors. These compounds aim to reduce the human response to trauma, addressing the significant unmet need in PTSD treatment. "Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone," Tennyson explained, adding that current treatments are limited, leaving a large addressable market. With Eurofins Discovery's expertise in research services, Graft Polymer is moving forward quickly and expects preclinical results by the end of November. Watch the full interview for insights into this groundbreaking PTSD research and stay updated on Graft Polymer’s progress. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future updates. #GraftPolymer #AnthonyTennyson #EurofinsDiscovery #PTSDTreatment #PharmacologyTesting #MentalHea#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
606 episoder
Tous les épisodes
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.